Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID-tunniste: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Transcriptional response networks for elucidating mechanisms of action of multitargeted agentsDasatinib and everolimus show synergistic growth inhibition with paclitaxel in an ovarian granulosa cell tumor modelLabel-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling (2016)
- Drug Discovery TodayCancer Research
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - UNSTABLE LDL - NOVEL MECHANISM OF ATHEROGENESIS AND LINK TO CARDIOVASCULAR DEATHS (2016)
- AtherosclerosisScientific Reports
(O2 Muu julkaisu ) - (2015)
(O2 Muu julkaisu ) - From drug response profiling to target addiction scoring in cancer cell models (2015)
- Disease Models and Mechanisms
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs (2015)
- Clinical Cancer ResearchBioinformatics
(O2 Muu julkaisu ) - Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)
- Expert Opinion on Drug Discovery
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)
- Cancer Research
(O2 Muu julkaisu ) - Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data (2015)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML (2015)
- Blood
(O2 Muu julkaisu ) - (2015)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
